Intelligent Bio Solutions Inc. (INBS) News
Follow Intelligent Bio Solutions Inc. (INBS) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 15 public stories across 11 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Intelligent Bio Solutions updates shares outstanding to 3,316,803 following warrant exercises
Intelligent Bio Solutions reported total common shares outstanding of 3,316,803 following warrant exercises and restricted stock issuance.Key Highlights:Original SEC Filing: INTELLIGENT BIO SOLUTIONS INC. [ INBS ] - 8-K
REGULATION | Sep 11, 2026, 09:04 PM UTC
L
Intelligent Bio Solutions to Host Virtual Fireside Chat on September 24th at 4:30 p.m. ET
Management to discuss FDA 510(k) submission, clinical data, and commercial progress outside the U.S.NEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. NASDAQ:INBS (“INBS” or the “Company”), a med
REGULATION | Sep 10, 2026, 12:34 PM UTC
L
INBS - Intelligent Bio Solutions to Host Virtual Fireside Chat on September 24th at 4:30 p.m. ET
INBS - Intelligent Bio Solutions to Host Virtual Fireside Chat on September 24th at 4:30 p.m. ET
EQUITY | Sep 10, 2026, 12:31 PM UTC
L
Intelligent Bio Solutions files FDA 510(k) for drug screening system
Intelligent Bio Solutions submitted a 510(k) to the FDA for its Intelligent Fingerprinting Drug Screening System after clinical studies showed Method Comparison accuracy above 98%.
REGULATION | Sep 09, 2026, 01:03 PM UTC
L
INBS submits FDA 510(k) package for drug screening system
INBS filed an FDA 510(k) package for an intelligent fingerprinting drug screening system, seeking U.S. market clearance.
REGULATION | Sep 09, 2026, 12:30 PM UTC
M
Intelligent Bio Solutions completes $5 million private placement with warrants
Intelligent Bio Solutions completed a $5.0 million private placement with a single institutional investor, issuing 2,036,659 pre-funded warrants at a combined price of $2.455 per unit, plus Series N-1 and N-2 warrants.
EQUITY | Sep 02, 2026, 09:04 PM UTC
L
Intelligent Bio Solutions posts >98% accuracy in multi-site study
Intelligent Bio Solutions said a multi-site Method Comparison Study showed above 98% accuracy, 94.6% sensitivity and 100% specificity for codeine.
REGULATION | Sep 01, 2026, 09:14 PM UTC
M
Intelligent Bio Solutions private placement up to $15M, at-the-market
Intelligent Bio Solutions announced a private placement of up to $15M to a single existing institutional investor, priced at-the-market under Nasdaq rules.
EQUITY | Sep 01, 2026, 12:37 PM UTC
L
INBS - Intelligent Bio Solutions Achieves Above 98% Accuracy in Method Comparison Study, Supporting Planned 2026 FDA 510 (k) Submission - Cl
INBS - Intelligent Bio Solutions Achieves Above 98% Accuracy in Method Comparison Study, Supporting Planned 2026 FDA 510 (k) Submission
REGULATION | Sep 01, 2026, 12:31 PM UTC
L
INBS: Non-invasive fingerprint drug testing drives growth and prepares for U.S. market entry
INBS: Non-invasive fingerprint drug testing drives growth and prepares for U.S. market entry
EQUITY | Aug 28, 2026, 02:05 PM UTC
L
Intelligent Bio Solutions reports 38% fiscal 2026 full-year revenue growth
Intelligent Bio Solutions said fiscal 2026 full-year revenue grew 38% year over year, driven by reader installed base and high-margin cartridge growth.
EQUITY | Aug 19, 2026, 12:30 PM UTC
L
Intelligent Bio Solutions secures ISO recertification for quality management
Intelligent Bio Solutions (INBS) states it strengthens its quality management credentials through ISO recertification.
REGULATION | Aug 17, 2026, 12:30 PM UTC
L
INBS - Intelligent Bio Solutions Completes Usability Study Supporting FDA 510 (k) Submission
INBS - Intelligent Bio Solutions Completes Usability Study Supporting FDA 510 (k) Submission
REGULATION | Aug 05, 2026, 12:30 PM UTC
L
INBS Completes Interference Study
INBS completes study on fingerprinting system
EQUITY | Aug 03, 2026, 12:31 PM UTC
L
INBS Intelligent Bio solutions completes Precision testing, strengthening FDA 510(k) submission package ahead of planned entry into multi-bi
INBS Intelligent Bio solutions completes Precision testing, strengthening FDA 510(k) submission package ahead of planned entry into multi-billion-dollar U.S. drug screening market
FX | Jul 21, 2026, 12:30 PM UTC